The once-weekly treatment unifying
superior efficacy1-4,28,30 and CV benefits1,5
SUPERIOR
GLYCAEMIC
CONTROL1,2,28,30*
SUPERIOR AND
SUSTAINED
WEIGHT LOSS1,2,5,28,30*
PROVEN
CV BENEFITS1,5†
For adults with type 2 diabetes and established CVD
2018 ADA/EASD consensus report recommends
GLP-1 RA therapy with proven CV benefit6
CV=cardiovascular; CVD=cardiovascular disease; ADA=American Diabetes Association;
EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction;
*Results apply to Ozempic® across SUSTAIN trials, which included placebo, Januvia®, Trulicity®,
Bydureon®, Lantus®, Invokana® and Victoza®.1,2,28,30
†In SUSTAIN 6, Ozempic® reduced CV risk (CV death, nonfatal MI or nonfatal stroke) versus
placebo in patients with type 2 diabetes at high CV risk treated with standard of care.1
JO21OZM00016.